Are your internal processes drowning out the patient voice?Greater patient involvement is among the stated aims of the ABPI, so why do companies up and down Share XAre your internal processes drowning out the patient voice?https://pharmaphorum.com/views-analysis-patients/internal-processes-drowning-patient-voice/
Transparency creates fruitful pharma-patient group partnershipsCollaboration between pharma and patient organisations can yield fantastic results – but conflict of interest concerns can stop Share XTransparency creates fruitful pharma-patient group partnershipshttps://pharmaphorum.com/views-analysis-patients/transparency-creates-fruitful-pharma-patient-group-partnerships/
Fair market value for patientsFair Market Value (FMV) payment is not a new concept to the life science industry. It has for Share XFair market value for patientshttps://pharmaphorum.com/views-analysis-patients/fair-market-value-for-patients/
From poison to lifeline – how my views on chemotherapy changed as a cancer patientCancer survivor Brooke Gant tells us about her experiences with chemotherapy. In 2017, I started off being a Share XFrom poison to lifeline – how my views on chemotherapy changed as a cancer patienthttps://pharmaphorum.com/views-analysis-patients/from-poison-to-lifeline-how-my-views-on-chemotherapy-changed-as-a-cancer-patient/
Boosting clinical trial recruitment through patient engagementOver the years, many hands have been wrung over clinical trial recruitment – low participation rates are common Share XBoosting clinical trial recruitment through patient engagementhttps://pharmaphorum.com/views-analysis-patients/boosting-clinical-trial-recruitment-through-patient-engagement/
The unmet needs of bleeding disorder patientsAhead of eyeforpharma Philadelphia 2019, we talk to speaker and haemophilia advocate Michelle Rice about the changing landscape Share XThe unmet needs of bleeding disorder patientshttps://pharmaphorum.com/views-analysis-patients/the-unmet-needs-of-bleeding-disorder-patients/
Success comes from listening to and working with patientsWith the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow Share XSuccess comes from listening to and working with patientshttps://pharmaphorum.com/views-analysis-patients/success-comes-from-listening-to-and-working-with-patients/
Pharma must put patients at the centre of the shift to value-based careThe pharma industry has been talking about the healthcare sector’s move to value-based care for some time. Even Share XPharma must put patients at the centre of the shift to value-based carehttps://pharmaphorum.com/views-analysis-patients/pharma-must-put-patients-at-the-centre-of-the-shift-to-value-based-care/
Listening to the myeloma patient voice is difficult – but it still needs to be doneOver the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – Share XListening to the myeloma patient voice is difficult – but it still needs to be donehttps://pharmaphorum.com/views-analysis-patients/listening-myeloma-patient-voice-difficult-but-needs-to-be-done/
